Education
About Us
Working with TipRanks
Follow Us
Citius Oncology, Inc. (CTOR)
:CTOR
Total Valuation
Citius Oncology has a market cap or net worth of $152.83M. The enterprise value is $315.05M.
Market Cap$152.83M
Enterprise Value$315.05M
Share Statistics
Citius Oncology has 83,513,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding83,513,440
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Citius Oncology’s return on equity (ROE) is -0.46 and return on invested capital (ROIC) is -40.93%.
Return on Equity (ROE)-0.46
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-40.93%
Return on Capital Employed (ROCE)-0.40
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Citius Oncology is 16.7. Citius Oncology’s PEG ratio is -0.08.
PE Ratio16.7
PS Ratio0.00
PB Ratio2.16
Price to Fair Value2.16
Price to FCF-20.41
Price to Operating Cash Flow-383.39
PEG Ratio-0.08
Income Statement
In the last 12 months, Citius Oncology had revenue of 0.00 and earned -21.15M in profits. Earnings per share was -0.30.
Revenue0.00
Gross Profit0.00
Operating Income-20.57M
Pretax Income-20.57M
Net Income-21.15M
EBITDA-20.57M
Earnings Per Share (EPS)-0.30
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Citius Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change69.31%
50-Day Moving Average1.86
200-Day Moving Average1.48
Relative Strength Index (RSI)37.49
Average Volume (3m)189.96K
Important Dates
Citius Oncology upcoming earnings date is Aug 12, 2025, After Close (Not Confirmed).
Last Earnings DateMay 14, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Citius Oncology as a current ratio of 0.34, with Debt / Equity ratio of 11.73%
Current Ratio0.34
Quick Ratio0.08
Debt to Market Cap0.04
Net Debt to EBITDA-0.18
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Citius Oncology has paid 576.00K in taxes.
Income Tax576.00K
Effective Tax Rate-0.03
Enterprise Valuation
Citius Oncology EV to EBITDA ratio is -5.02, with an EV/FCF ratio of -21.19.
EV to Sales0.00
EV to EBITDA-5.02
EV to Free Cash Flow-21.19
EV to Operating Cash Flow817.22
Balance Sheet
Citius Oncology has $112.00 in cash and marketable securities with $3.80M in debt, giving a net cash position of -$3.80M billion.
Cash & Marketable Securities$112.00
Total Debt$3.80M
Net Cash-$3.80M
Net Cash Per Share-$0.05
Tangible Book Value Per Share-$0.38
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Citius Oncology is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside227.87% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―